Baxter’s Clinolipid Could Offer Safety Advantages While Mitigating Shortage
This article was originally published in The Pink Sheet Daily
Executive Summary
Though it doesn’t have a formal labeling claim, olive-oil based parenteral nutrition drug provides marketing advantages compared to soybean fat emulsions drugs, while helping to ease shortage.
You may also be interested in...
FDA Likely To Allow Outcomes Studies Post-Approval For Fat Emulsion Drugs
Agency will probably clear products based on non-inferiority studies with nutrition endpoints, but ultimately wants clinical outcomes trials.
FDA Shutdown Hangover Hurts Biosimilars, May Benefit Some ANDAs
As normal operations – and normal budget worries – resume, the agency has some meetings to reschedule.
FDA In Twilight: Gov’t Shutdown Has Not Slowed Rx Operations Too Visibly Yet
Shutdown puts API shipments on a slow boat, but reviews of existing products can proceed with carry-over funds, even as new applications cannot be filed. CDC has largely halted its influenza program and NIH has ceased enrolling new patients in its clinical center.